RNAi Drug Delivery Market Report: Trends, Forecast and Competitive Analysis to 2030
Get it in 2 to 4 weeks by ordering today
RNAi Drug Delivery Trends and Forecast
The future of the global RNAi drug delivery market looks promising with opportunities in the infectious disease, cardiology, oncology, neurology, ophthalmology, urology, and metabolic disorder markets. The global RNAi drug delivery market is expected to reach an estimated $3.5 billion by 2030 with a CAGR of 20.5% from 2024 to 2030. The major drivers for this market are increasing investments in pharmaceutical research and development and growing prevalence of genetic disorders and chronic diseases.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
RNAi Drug Delivery by Segment
The study includes a forecast for the global RNAi drug delivery by technology, application, and region.
RNAi Drug Delivery Market by Technology [Shipment Analysis by Value from 2018 to 2030]:
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies RNAi drug delivery companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the RNAi drug delivery companies profiled in this report include-
Lucintel forecasts that nanoparticle drug delivery is expected to witness the highest growth over the forecast period.
North America is expected to witness highest growth over the forecast period.
Features of the Global RNAi Drug Delivery Market
Market Size Estimates: RNAi drug delivery market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: RNAi drug delivery market size by technology, application, and region in terms of value ($B).
Regional Analysis: RNAi drug delivery market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different technologies, applications, and regions for the RNAi drug delivery market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the RNAi drug delivery market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the RNAi drug delivery market size?
Answer: The global RNAi drug delivery market is expected to reach an estimated $3.5 billion by 2030.
Q2. What is the growth forecast for RNAi drug delivery market?
Answer: The global RNAi drug delivery market is expected to grow with a CAGR of 20.5% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the RNAi drug delivery market?
Answer: The major drivers for this market are increasing investments in pharmaceutical research and development and growing prevalence of genetic disorders and chronic diseases.
Q4. What are the major segments for RNAi drug delivery market?
Answer: The future of the RNAi drug delivery market looks promising with opportunities in the infectious disease, cardiology, oncology, neurology, ophthalmology, urology, and metabolic disorder markets.
Q5. Who are the key RNAi drug delivery market companies?
Answer: Some of the key RNAi drug delivery companies are as follows:
Answer: Lucintel forecasts that nanoparticle drug delivery is expected to witness the highest growth over the forecast period.
Q7. In RNAi drug delivery market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness highest growth over the forecast period.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the RNAi drug delivery market by technology (nanoparticle drug delivery, pulmonary drug delivery, nucleic acid drug delivery, and aptamer drug delivery), application (infectious disease, cardiology, oncology, neurology, ophthalmology, urology, metabolic disorders, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to RNAi Drug Delivery Market, RNAi Drug Delivery Market Size, RNAi Drug Delivery Market Growth, RNAi Drug Delivery Market Analysis, RNAi Drug Delivery Market Report, RNAi Drug Delivery Market Share, RNAi Drug Delivery Market Trends, RNAi Drug Delivery Market Forecast, RNAi Drug Delivery Companies, write Lucintel analyst at email: [email protected]. We will be glad to get back to you soon.
RNAi Drug Delivery Trends and Forecast
The future of the global RNAi drug delivery market looks promising with opportunities in the infectious disease, cardiology, oncology, neurology, ophthalmology, urology, and metabolic disorder markets. The global RNAi drug delivery market is expected to reach an estimated $3.5 billion by 2030 with a CAGR of 20.5% from 2024 to 2030. The major drivers for this market are increasing investments in pharmaceutical research and development and growing prevalence of genetic disorders and chronic diseases.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
RNAi Drug Delivery by Segment
The study includes a forecast for the global RNAi drug delivery by technology, application, and region.
RNAi Drug Delivery Market by Technology [Shipment Analysis by Value from 2018 to 2030]:
- Nanoparticle Drug Delivery
- Pulmonary Drug Delivery
- Nucleic Acid Drug Delivery
- Aptamer Drug Delivery
- Infectious Disease
- Cardiology
- Oncology
- Neurology
- Ophthalmology
- Urology
- Metabolic Disorders
- Others
- North America
- Europe
- Asia Pacific
- The Rest of the World
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies RNAi drug delivery companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the RNAi drug delivery companies profiled in this report include-
- Alnylam Pharmaceuticals
- Arrowhead Pharmaceuticals
- CureVac
- Dicerna Pharmaceuticals
- Gradalis
- Ionis Pharmaceuticals
- Merck
- Moderna
- Quark Pharmaceuticals
- Silence Therapeutics
Lucintel forecasts that nanoparticle drug delivery is expected to witness the highest growth over the forecast period.
North America is expected to witness highest growth over the forecast period.
Features of the Global RNAi Drug Delivery Market
Market Size Estimates: RNAi drug delivery market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: RNAi drug delivery market size by technology, application, and region in terms of value ($B).
Regional Analysis: RNAi drug delivery market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different technologies, applications, and regions for the RNAi drug delivery market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the RNAi drug delivery market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the RNAi drug delivery market size?
Answer: The global RNAi drug delivery market is expected to reach an estimated $3.5 billion by 2030.
Q2. What is the growth forecast for RNAi drug delivery market?
Answer: The global RNAi drug delivery market is expected to grow with a CAGR of 20.5% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the RNAi drug delivery market?
Answer: The major drivers for this market are increasing investments in pharmaceutical research and development and growing prevalence of genetic disorders and chronic diseases.
Q4. What are the major segments for RNAi drug delivery market?
Answer: The future of the RNAi drug delivery market looks promising with opportunities in the infectious disease, cardiology, oncology, neurology, ophthalmology, urology, and metabolic disorder markets.
Q5. Who are the key RNAi drug delivery market companies?
Answer: Some of the key RNAi drug delivery companies are as follows:
- Alnylam Pharmaceuticals
- Arrowhead Pharmaceuticals
- CureVac
- Dicerna Pharmaceuticals
- Gradalis
- Ionis Pharmaceuticals
- Merck
- Moderna
- Quark Pharmaceuticals
- Silence Therapeutics
Answer: Lucintel forecasts that nanoparticle drug delivery is expected to witness the highest growth over the forecast period.
Q7. In RNAi drug delivery market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness highest growth over the forecast period.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the RNAi drug delivery market by technology (nanoparticle drug delivery, pulmonary drug delivery, nucleic acid drug delivery, and aptamer drug delivery), application (infectious disease, cardiology, oncology, neurology, ophthalmology, urology, metabolic disorders, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to RNAi Drug Delivery Market, RNAi Drug Delivery Market Size, RNAi Drug Delivery Market Growth, RNAi Drug Delivery Market Analysis, RNAi Drug Delivery Market Report, RNAi Drug Delivery Market Share, RNAi Drug Delivery Market Trends, RNAi Drug Delivery Market Forecast, RNAi Drug Delivery Companies, write Lucintel analyst at email: [email protected]. We will be glad to get back to you soon.
1. EXECUTIVE SUMMARY
2. GLOBAL RNAI DRUG DELIVERY MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global RNAi Drug Delivery Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global RNAi Drug Delivery Market by Technology
3.3.1: Nanoparticle Drug Delivery
3.3.2: Pulmonary Drug Delivery
3.3.3: Nucleic Acid Drug Delivery
3.3.4: Aptamer Drug Delivery
3.4: Global RNAi Drug Delivery Market by Application
3.4.1: Infectious Disease
3.4.2: Cardiology
3.4.3: Oncology
3.4.4: Neurology
3.4.5: Ophthalmology
3.4.6: Urology
3.4.7: Metabolic Disorders
3.4.8: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global RNAi Drug Delivery Market by Region
4.2: North American RNAi Drug Delivery Market
4.2.1: North American RNAi Drug Delivery Market by Technology: Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery, and Aptamer Drug Delivery
4.2.2: North American RNAi Drug Delivery Market by Application: Infectious Disease, Cardiology, Oncology, Neurology, Ophthalmology, Urology, Metabolic Disorders, and Others
4.3: European RNAi Drug Delivery Market
4.3.1: European RNAi Drug Delivery Market by Technology: Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery, and Aptamer Drug Delivery
4.3.2: European RNAi Drug Delivery Market by Application: Infectious Disease, Cardiology, Oncology, Neurology, Ophthalmology, Urology, Metabolic Disorders, and Others
4.4: APAC RNAi Drug Delivery Market
4.4.1: APAC RNAi Drug Delivery Market by Technology: Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery, and Aptamer Drug Delivery
4.4.2: APAC RNAi Drug Delivery Market by Application: Infectious Disease, Cardiology, Oncology, Neurology, Ophthalmology, Urology, Metabolic Disorders, and Others
4.5: ROW RNAi Drug Delivery Market
4.5.1: ROW RNAi Drug Delivery Market by Technology: Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery, and Aptamer Drug Delivery
4.5.2: ROW RNAi Drug Delivery Market by Application: Infectious Disease, Cardiology, Oncology, Neurology, Ophthalmology, Urology, Metabolic Disorders, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global RNAi Drug Delivery Market by Technology
6.1.2: Growth Opportunities for the Global RNAi Drug Delivery Market by Application
6.1.3: Growth Opportunities for the Global RNAi Drug Delivery Market by Region
6.2: Emerging Trends in the Global RNAi Drug Delivery Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global RNAi Drug Delivery Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global RNAi Drug Delivery Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: Alnylam Pharmaceuticals
7.2: Arrowhead Pharmaceuticals
7.3: CureVac
7.4: Dicerna Pharmaceuticals
7.5: Gradalis
7.6: Ionis Pharmaceuticals
7.7: Merck
7.8: Moderna
7.9: Quark Pharmaceuticals
7.10: Silence Therapeutics
2. GLOBAL RNAI DRUG DELIVERY MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global RNAi Drug Delivery Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global RNAi Drug Delivery Market by Technology
3.3.1: Nanoparticle Drug Delivery
3.3.2: Pulmonary Drug Delivery
3.3.3: Nucleic Acid Drug Delivery
3.3.4: Aptamer Drug Delivery
3.4: Global RNAi Drug Delivery Market by Application
3.4.1: Infectious Disease
3.4.2: Cardiology
3.4.3: Oncology
3.4.4: Neurology
3.4.5: Ophthalmology
3.4.6: Urology
3.4.7: Metabolic Disorders
3.4.8: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global RNAi Drug Delivery Market by Region
4.2: North American RNAi Drug Delivery Market
4.2.1: North American RNAi Drug Delivery Market by Technology: Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery, and Aptamer Drug Delivery
4.2.2: North American RNAi Drug Delivery Market by Application: Infectious Disease, Cardiology, Oncology, Neurology, Ophthalmology, Urology, Metabolic Disorders, and Others
4.3: European RNAi Drug Delivery Market
4.3.1: European RNAi Drug Delivery Market by Technology: Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery, and Aptamer Drug Delivery
4.3.2: European RNAi Drug Delivery Market by Application: Infectious Disease, Cardiology, Oncology, Neurology, Ophthalmology, Urology, Metabolic Disorders, and Others
4.4: APAC RNAi Drug Delivery Market
4.4.1: APAC RNAi Drug Delivery Market by Technology: Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery, and Aptamer Drug Delivery
4.4.2: APAC RNAi Drug Delivery Market by Application: Infectious Disease, Cardiology, Oncology, Neurology, Ophthalmology, Urology, Metabolic Disorders, and Others
4.5: ROW RNAi Drug Delivery Market
4.5.1: ROW RNAi Drug Delivery Market by Technology: Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery, and Aptamer Drug Delivery
4.5.2: ROW RNAi Drug Delivery Market by Application: Infectious Disease, Cardiology, Oncology, Neurology, Ophthalmology, Urology, Metabolic Disorders, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global RNAi Drug Delivery Market by Technology
6.1.2: Growth Opportunities for the Global RNAi Drug Delivery Market by Application
6.1.3: Growth Opportunities for the Global RNAi Drug Delivery Market by Region
6.2: Emerging Trends in the Global RNAi Drug Delivery Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global RNAi Drug Delivery Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global RNAi Drug Delivery Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: Alnylam Pharmaceuticals
7.2: Arrowhead Pharmaceuticals
7.3: CureVac
7.4: Dicerna Pharmaceuticals
7.5: Gradalis
7.6: Ionis Pharmaceuticals
7.7: Merck
7.8: Moderna
7.9: Quark Pharmaceuticals
7.10: Silence Therapeutics
